Clin2
NCT05480449Possibly a fitRecruiting

Personalized CAR-T for children with high-risk B-ALL

B Cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma

Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.

This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
115 people
Ages
birth to 29 years
Study type
Interventional

Who can take part

  • You (or your child) have B-ALL or another listed B-cell leukemia that shows CD19 on tests
  • Your disease fits a specific situation (like relapse, not responding, or early return after similar cell therapy)
  • You are between 0 and 29 years old
  • Your organs and breathing/heart are strong enough based on blood tests and heart/lung checks
  • You can’t have certain infections or illnesses (including HIV, active hepatitis B/C, uncontrolled infection)
  • You can’t be pregnant or breastfeeding, and you/your family must use birth control if able to have a pregnancy

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05674175Recruiting· Phase 1/Phase 2
Test two engineered immune cell treatments for B-cell leukemia

This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.

Philadelphia, Pennsylvania
NCT05442515Recruiting· Phase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth

This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.

Bethesda, Maryland
NCT06559189Recruiting· Phase 1
A new CAR T therapy for children with relapsed B-ALL

This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.

Aurora, Colorado
NCT07277504Not yet recruiting· Early Phase 1
Personalized CAR T-cell therapy for B-cell acute lymphoblastic leukemia

This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.

Chengdu, Sichuan
NCT06080191Recruiting· Phase 1
Donor CAR T cells for pediatric B-ALL relapse

This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.

Rome, Italy
NCT07695012Recruiting· Early Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia

This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.

Rawalpindi

Hear when a new B Cell Acute Lymphoblastic Leukemia (B-ALL) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.